Season's Savings | ₹5/mo for 3 months

₹199/month after first 3 months. Renews automatically. Terms apply.
Metastatic TNBC cannot wait cover art

Metastatic TNBC cannot wait

Metastatic TNBC cannot wait

Listen for free

View show details
About this listen

In this video podcast, Prof. Giuseppe Curigliano and Dr Javier Cortés explore how TROP2-directed antibody–drug conjugates (ADCs) are shaping 1st line treatment for metastatic triple-negative breast cancer (TNBC).

Key clinical takeaways:

  • Earlier placement: TROPION-Breast02 and ASCENT-03 support 1st line TROP2 ADC use in defined patients who are not candidates for an ICI; ASCENT-04 supports SG plus pembrolizumab in the studied PD-L1-positive population 
  • Individualised selection: Apply each trial to the appropriate patient. Consider disease characteristics, prior therapy, schedule and AE profile; avoid indirect comparisons between Dato-DXd and SG 
  • Proactive safety: Translate the Dato-DXd and SG safety evidence into treatment-specific prevention, monitoring and escalation plans before dose 1 

You can also watch a video of the experts in conversation and download the accompanying transcript on our website: https://cor2ed.com/breast-cancer-connect/programmes/metastatic-tnbc

Or watch on YouTube: https://youtu.be/3gr7g_IeRtU

Follow us on social media:

LinkedIn: https://www.linkedin.com/company/breastcancerconnect/home/

X: https://x.com/BreastCaConnect

Instagram: https://www.instagram.com/cor2edmeded 

Subscribe to this channel to stay up to date with new medical education programmes as they’re released.

This content is intended for healthcare professionals only.

This podcast is supported by an Independent Education Grant from AstraZeneca

This podcast is developed by cor2ed.com

Published on October 2026

adbl_web_anon_alc_button_suppression_t1
No reviews yet